Bicycle Therapeutics plc American Depositary Shares
BCYC Real Time Price USDRecent trades of BCYC by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in BCYC holdings by institutional investors
Quarterly net insider trading by BCYC's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$150,000 Oct 19, 2026 Issue: Pharmacy Health Issues
-
$150,000 Jul 05, 2026 Issue: Health Issues Pharmacy
-
$150,000 Apr 20, 2026 Issue: Health Issues Pharmacy
Former government officials who have lobbied for BCYC
2 former government officials from 2 congressional offices at 1 lobbying firm have lobbied for BCYC, most recently Oct 19, 2026.
-
Alanna Temme House Legislative Director, U.S. Representative Jon Porter -
Sophie Khanahmadi House Legislative Asst., Rep. Martha Roby; Legislative Asst., Rep. Lee Terry; Staff Asst./LC, Senator Jeff Sessions
BCYC Estimated quarterly lobbying spending
BCYC Revenue by Segment or Geography
New BCYC patent grants
-
Patent Title: Methods and compositions Jun. 06, 2017
-
Patent Title: Multispecific peptides Jun. 06, 2017
-
Patent Title: Connector compound peptide phage display May. 23, 2017
-
Patent Title: Structured peptide processing May. 09, 2017
-
Patent Title: Peptide libraries Dec. 13, 2016
-
Patent Title: Structured peptide processing Jul. 15, 2014
-
Patent Title: Multispecific peptides Apr. 01, 2014
-
Patent Title: Methods and compositions Mar. 25, 2014
Federal grants, loans, and purchases
Estimated quarterly amount awarded to BCYC from public contracts
Recent insights relating to BCYC
Recent picks made for BCYC stock on CNBC
ETFs with the largest estimated holdings in BCYC
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $BCYC stock a Buy, Sell, or Hold?
- What is the price target for $BCYC stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $BCYC stock?
- Who owns the most shares of $BCYC stock?
- What funds own $BCYC stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view BCYC Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
- Address Cambridge, X0
- Market Cap 247.4 million
- Employees 288
- Industrial Classification Pharmaceutical Preparations
Bicycle Therapeutics plc American Depositary Shares (BCYC) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for Bicycle Therapeutics plc American Depositary Shares (BCYC).
Quiver Premium charts BCYC's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at BCYC, per a recent SEC DEF 14A filing. We estimate that the median employee at BICYCLE THERAPEUTICS PLC is paid $203,298.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|